CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 119 filers reported holding CYTOMX THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $295,677 | -25.9% | 242,358 | +32.4% | 0.00% | – |
| Q1 2024 | $399,108 | -54.5% | 183,077 | -67.6% | 0.00% | – |
| Q4 2023 | $876,252 | -4.1% | 565,324 | -20.1% | 0.00% | – |
| Q3 2023 | $913,278 | -27.0% | 707,968 | -2.7% | 0.00% | – |
| Q2 2023 | $1,251,092 | -41.3% | 727,380 | -48.5% | 0.00% | – |
| Q1 2023 | $2,131,206 | +85.9% | 1,411,394 | +96.9% | 0.00% | – |
| Q4 2022 | $1,146,634 | +12.7% | 716,646 | +2.1% | 0.00% | – |
| Q3 2022 | $1,017,000 | -21.0% | 701,572 | -0.2% | 0.00% | – |
| Q2 2022 | $1,287,000 | -31.3% | 703,209 | +0.2% | 0.00% | – |
| Q1 2022 | $1,874,000 | -19.3% | 701,817 | +30.8% | 0.00% | – |
| Q4 2021 | $2,322,000 | -56.4% | 536,435 | -48.7% | 0.00% | – |
| Q3 2021 | $5,322,000 | -19.6% | 1,045,620 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $6,619,000 | -18.1% | 1,045,620 | +0.0% | 0.00% | 0.0% |
| Q1 2021 | $8,082,000 | +18.0% | 1,045,607 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $6,849,000 | +24.9% | 1,045,607 | +26.8% | 0.00% | 0.0% |
| Q3 2020 | $5,485,000 | -20.6% | 824,907 | -0.5% | 0.00% | 0.0% |
| Q2 2020 | $6,906,000 | +8.7% | 828,973 | +0.0% | 0.00% | 0.0% |
| Q1 2020 | $6,355,000 | -7.7% | 828,613 | -0.0% | 0.00% | 0.0% |
| Q4 2019 | $6,885,000 | +5.5% | 828,618 | -6.3% | 0.00% | 0.0% |
| Q3 2019 | $6,529,000 | -56.0% | 884,726 | -33.1% | 0.00% | -50.0% |
| Q2 2019 | $14,847,000 | -35.4% | 1,323,211 | -38.1% | 0.00% | -33.3% |
| Q1 2019 | $22,992,000 | -74.3% | 2,138,779 | -63.9% | 0.00% | -75.0% |
| Q4 2018 | $89,458,000 | -28.3% | 5,924,431 | -12.2% | 0.01% | -14.3% |
| Q3 2018 | $124,774,000 | -6.6% | 6,744,553 | +15.4% | 0.01% | -6.7% |
| Q2 2018 | $133,586,000 | -18.9% | 5,843,626 | +0.9% | 0.02% | -25.0% |
| Q1 2018 | $164,774,000 | +35.5% | 5,791,673 | +0.5% | 0.02% | +42.9% |
| Q4 2017 | $121,621,000 | +21.0% | 5,761,294 | +4.2% | 0.01% | +16.7% |
| Q3 2017 | $100,482,000 | +17.6% | 5,530,105 | +0.3% | 0.01% | +9.1% |
| Q2 2017 | $85,444,000 | -9.7% | 5,512,459 | +0.6% | 0.01% | -8.3% |
| Q1 2017 | $94,600,000 | +57.6% | 5,477,727 | +0.3% | 0.01% | +50.0% |
| Q4 2016 | $60,009,000 | -29.7% | 5,460,352 | +0.3% | 0.01% | -27.3% |
| Q3 2016 | $85,350,000 | +54.4% | 5,443,262 | +0.6% | 0.01% | +37.5% |
| Q2 2016 | $55,295,000 | -20.8% | 5,413,165 | +0.0% | 0.01% | -20.0% |
| Q1 2016 | $69,811,000 | -38.1% | 5,411,681 | +0.1% | 0.01% | -33.3% |
| Q4 2015 | $112,773,000 | – | 5,403,643 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners IX LLC | 4,244,381 | $43,378,000 | 100.00% |
| VHCP Management II, LLC | 577,831 | $5,905,000 | 3.56% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 71,366 | $729,000 | 2.45% |
| Casdin Capital, LLC | 234,179 | $2,392,000 | 2.38% |
| BVF INC/IL | 606,138 | $6,192,000 | 1.32% |
| Opaleye Management Inc. | 160,000 | $1,634,000 | 1.09% |
| Redmile Group, LLC | 733,899 | $7,497,000 | 0.72% |
| VHCP Management, LLC | 64,200 | $656,000 | 0.68% |
| Montecito Bank & Trust | 146,544 | $1,497,000 | 0.63% |
| Cormorant Asset Management, LP | 371,636 | $3,796,000 | 0.54% |